Mundipharma Pharmaceuticals Ltd is pleased to announce the launch of Targin 40/20mg and 2.5/1.25mg prolonged-release tablets (40/20mg and 2.5/1.25mg oxycodone/naloxone). Targin contains the opioid analgesic oxycodone and is indicated for the treatment of severe pain, which can be adequately managed only with opioid analgesics. A recognised side-effect of opioid treatment is opioid-induced constipation (OIC). The severity of OIC experienced can lead to patients reducing their dose of medication or ceasing treatment completely. Targin is designed to reduce this problem with the addition of the opioid antagonist naloxone which is added to counteract OIC by blocking the action of oxycodone at